In recent years, a number of novel biomarkers, such as AFP [41, 42], glypican 3 [43], Osteopontin [44], CXCL1 [45], UQCRH [46], TIP30 [47], neutrophil–lymphocyte ratio [48], have emerged for diagnosing HCC and predicting patient outcome. Here, HTATIP2 is linked to hepatocellular carcinoma.